Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Work In Process: 2023-2025

Historic Work In Process for Krystal Biotech (KRYS) over the last 2 years, with Sep 2025 value amounting to $15.8 million.

  • Krystal Biotech's Work In Process rose 147.28% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year increase of 147.28%. This contributed to the annual value of $10.7 million for FY2024, which is 235.30% up from last year.
  • As of Q3 2025, Krystal Biotech's Work In Process stood at $15.8 million, which was up 3.38% from $15.3 million recorded in Q2 2025.
  • Over the past 5 years, Krystal Biotech's Work In Process peaked at $15.8 million during Q3 2025, and registered a low of $3.2 million during Q4 2023.
  • Over the past 3 years, Krystal Biotech's median Work In Process value was $7.6 million (recorded in 2024), while the average stood at $9.0 million.
  • Data for Krystal Biotech's Work In Process shows a peak YoY spiked of 235.30% (in 2024) over the last 5 years.
  • Krystal Biotech's Work In Process (Quarterly) stood at $3.2 million in 2023, then surged by 235.30% to $10.7 million in 2024, then surged by 147.28% to $15.8 million in 2025.
  • Its Work In Process was $15.8 million in Q3 2025, compared to $15.3 million in Q2 2025 and $8.9 million in Q1 2025.